Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3475766 · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3475766 - IV | EXPERIMENTAL | LY3475766 administered intravenously (IV) to participants with dyslipidemia |
| Placebo - IV | PLACEBO_COMPARATOR | Placebo administered IV to participants with dyslipidemia |
| LY3475766 - SC | EXPERIMENTAL | LY3475766 administered subcutaneously (SC) to participants with dyslipidemia |
| Placebo - SC | PLACEBO_COMPARATOR | Placebo administered SC to participants with dyslipidemia |
| Name | Type | Description |
|---|---|---|
| LY3475766 - IV | DRUG | Administered IV |
| LY3475766 - SC | DRUG | Administered SC |
| Placebo - IV | DRUG | Administered IV |
| Placebo - SC | DRUG | Administered SC |
Inclusion Criteria: * Are overtly healthy males or females, apart from dyslipidemia * Male participants must agree to adhere to contraception restrictions * Female participants must be of nonchildbearing potential and include those who are infertile due to surgical sterilization or those who are po...
LY3475766 is an investigational small molecule being developed for the treatment of dyslipidemias, a group of disorders characterized by abnormal levels of lipids in the blood. It is being studied in the cardiovascular therapeutic area. The drug is currently in Phase 1 clinical development and has not yet been approved by regulatory authorities.
The specific molecular target of LY3475766 has not been disclosed in available information. As a small molecule intended for dyslipidemias, it is presumed to modulate lipid metabolism, but the exact mechanism of action remains under investigation in clinical trials.
LY3475766 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug for the treatment of dyslipidemias.
LY3475766 is in Phase 1 clinical development. It is an investigational drug that has not yet received regulatory approval. The Phase 1 trial has been completed, and the drug remains in early-stage clinical evaluation for the treatment of dyslipidemias.
LY3475766 has one completed Phase 1 clinical trial registered under the identifier NCT04052594. This study, titled 'A Study of LY3475766 in Healthy Participants,' was conducted in the United States and enrolled 48 participants. The trial was randomized, double-blind, and placebo-controlled, and it included healthy volunteers aged 18 years and older.
No alternative names for LY3475766 have been disclosed. The drug is identified solely by its compound number LY3475766 in clinical trial registrations and available information. It is a distinct investigational agent being developed by Eli Lilly and Company for dyslipidemias.